Monday, October 16, 2017 6:03:29 AM
12-Oct-2017 18:27:28
Adds advisory: updates with comments from news conference, byline
By Julie Steenhuysen
Oct 12 (Reuters) - The Trump Administration threw its support behind a public-private partnership with 11 drug companies to advance a new class of drugs that uses the body's immune system to fight cancer.
The five-year collaboration is part of the Cancer Moonshot, a program started during the Obama administration and led by former Vice President Joe Biden, whose son Beau died of brain cancer.
The Partnership for Accelerating Cancer Therapies or PACT will devote $215 million to identify and test chemical signatures in the body that will help predict which patients will benefit from cancer immunotherapy.
Drug industry partners include AbbVie ABBV.N, Roche Holding AG ROG.S and Bristol-Myers Squibb BMY.N, whose drug Opdivo works by enlisting the body's defenses to fight tumors.
Merck & Co Inc MRK.N, whose Keytruda leads the fast-expanding field of immunotherapies, is not involved.
In a Thursday press conference announcing the collaboration, Reed Cordish, who heads the Office of American Innovation, an initiative led by President Donald Trump's son-in-law Jared Kushner, said the program represents the "type of collaboration and partnership between the private sector and government that this administration is trying to foster across many sectors."
Eric Hargan, the newly tapped Acting Secretary for the Department of Health and Human Services, told reporters: "Under President Trump, we are going to continue making significant investments in cancer cures. Advancing great American medicine and science is a top, top priority for this administration."
Plans for the partnership began two years ago under the leadership of Dr. Francis Collins, director of the National Institutes of Health. Collins said the group will work to explain why cancer immunotherapies, which have transformed treatment for melanoma, leukemia and some other cancers, do not work for more patients.
"By standardizing and validating biomarkers for immunotherapy while also developing and exploring new biomarkers, we hope to advance rapidly toward a new future of precision oncology that benefits all patients," Collins told the briefing.
Pfizer Inc PFE.N, Johnson & Johnson JNJ.N, Amgen Inc AMGN.O, Celgene Corp CELG.O, Gilead Sciences Inc GILD.O and GlaxoSmithKline Plc GSK.L are part of the effort, NIH said.
The 11 partners would contribute up to $55 million, while NIH would add about $160 million, based on availability of funds.
The partnership will be managed by the Foundation for the National Institutes of Health.
(Editing by James Dalgleish)
Recent CDMO News
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM